FDA 510(k) Clearance for Medical Device-Drug Combination Product: Bone Cement with Antibiotic

1. The Situation

A European medical device manufacturer wanted to submit a traditional 510(k) to the FDA for its bone cement that included an antibiotic. Because both the cement and the antibiotic are regulated components, the product met the definition of a combination product. This changed the regulatory pathway and submission requirements for FDA clearance.

2. The Regulatory Challenge

Combination products must comply with two separate Quality System Regulations: 21 CFR 820 for medical devices and 21 CFR 211 for finished pharmaceuticals. The manufacturer needed to align formulation, labeling, testing, and pre-submission data with both sets of regulations while demonstrating that the product met all safety and effectiveness standards for the intended use in orthopedic procedures.

3. The Solution Strategy

A comprehensive regulatory approach was implemented to address the unique requirements of the combination product. All formulation, labeling, testing, and pre-submission data were reviewed and aligned with the applicable regulations for both medical devices and pharmaceuticals. Pre-submission meetings with the FDA were used to confirm flexibility on antibiotic concentrations and specific test requirements, reducing the risk of additional data requests during review.

4. Key Execution Steps

4.1 Pre-Submission Planning and FDA Engagement

Pre-submission discussions with the FDA clarified the classification and data expectations. The agency confirmed that the submission could proceed under the traditional 510(k) pathway while addressing combination product considerations. This early engagement streamlined the review process and prevented major deficiencies later.

4.2 Quality System Compliance

The manufacturer’s quality system was verified to meet both 21 CFR 820 (QSR for medical devices) and 21 CFR 211 (GMP for pharmaceuticals). All manufacturing processes, controls, and documentation were updated to satisfy the dual regulatory standards.

4.3 Formulation, Labeling, and Testing Review

Detailed review of the bone cement formulation ensured compatibility between the device component and the antibiotic. Labeling was revised to meet both device and drug requirements. Testing plans were developed and executed to demonstrate safety, effectiveness, and stability of the combined product.

4.4 Preclinical Testing Coordination

Laboratories capable of performing the required preclinical testing were identified and contracted. All testing protocols were reviewed for compliance with both device and pharmaceutical regulations, and results were compiled into the submission package.

4.5 Submission and FDA Interaction

The complete 510(k) submission was prepared and submitted to the FDA in November. In January, all FDA questions and requests for additional information were addressed promptly and thoroughly. The FDA cleared the combination product for sale in the United States in March.

5. The Outcome

The manufacturer received FDA 510(k) clearance for the bone cement with antibiotic in just five months. The product is now authorized for marketing in the US, demonstrating that a well-planned regulatory strategy can successfully navigate the complexities of combination product submissions.

6. Critical Success Factors

• Early and proactive engagement with the FDA through pre-submission meetings.
• Alignment of all documentation with dual quality system regulations (21 CFR 820 and 21 CFR 211).
• Thorough review and optimization of formulation, labeling, and testing data.
• Efficient response to FDA information requests during the review period.
• Coordinated management of preclinical testing and data compilation.

This case shows that combination products can achieve rapid FDA clearance when regulatory requirements for both device and drug components are addressed systematically from the outset.